 The prevalence and costs associated with Alzheimers disease AD are projected to increase exponentially owing to the unprecedented expansion in the elderly segment of the United States population. Given this looming specter, delaying the onset of AD symptoms and curbing the progression of the underlying disease process has become a national public health imperative U.S. DHHS 2014. Delaying symptom onset by as little as 5 years could reduce the prevalence of AD by half U.S. DHHS 2014, Khachaturian 2009. Unfortunately, currently available drug treatments for AD are not curative. Similarly, clinical trials testing novel disease-modifying therapeutics have been disappointing Sperling 2011. The urgency of alternative approaches for halting the global crisis posed by AD cannot be overstated. 